Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522950 · ClinicalTrials.gov registry record · Phase 2
A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT01522950 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 76 participants.
The verdict
NCT01522950, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study comparing the efficacy of nebivolol and atenolol at improving small artery elasticity and reducing cardiovascular disease risk in subjects with early vascular disease. Approximately 75 subjects with borderline/elevated blood pressures and impaired endothelial function, as measured by arterial elasticity scores, will be recruited and assigned to treatment groups using a block randomization scheme. Patients will be randomly allocated to nebivolol, atenolol or placebo, and then followed for 9 months.
Interventions
- DRUG placebo
- DRUG Nebivolol
- DRUG atenolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2010-05 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522950
The ClinicalTrials.gov registry entry for NCT01522950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01522950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522950 about?
NCT01522950 is a clinical study titled "A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function". This is a randomized, double-blind, placebo-controlled study comparing the efficacy of nebivolol and atenolol at improving small artery elasticity and reducing cardiovascular disease risk in subjects with early vascular disease. Approximately 75 subjects with borderline/elevated blood pressures and ...
What is the current status of trial NCT01522950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2010-05. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01522950?
The interventions under investigation include: placebo (DRUG), Nebivolol (DRUG), atenolol (DRUG).
Who is sponsoring clinical trial NCT01522950?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.